4.8 Article

GARP on hepatic stellate cells is essential for the development of liver fibrosis

期刊

JOURNAL OF HEPATOLOGY
卷 79, 期 5, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2023.05.043

关键词

GARP; hepatic stellate cells (HSCs); liver fibrosis; TGF-I3; natural killer T (NKT) cells; endothelin-1 (ET-1)

向作者/读者索取更多资源

The expression of GARP on hepatic stellate cells (HSCs) drives the development of liver fibrosis through cell contraction-mediated activation of latent TGF-I3. This finding highlights the potential of GARP on HSCs as a promising target for the treatment of liver fibrosis.
Background & Aims: Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-I3 docking molecule. While the immune regulatory properties of GARP on blood cells have been studied, the function of GARP on tissue stromal cells remains unclear. Here, we investigate the role of GARP expressed on hepatic stellate cells (HSCs) in the development of liver fibrosis. Methods: The function of GARP on HSCs was explored in toxin-induced and metabolic liver fibrosis models, using conditional GARP-deficient mice or a newly generated inducible system for HSC-specific gene ablation. Primary mouse and human HSCs were isolated to evaluate the contribution of GARP to the activation of latent TGF-I3. Moreover, cell contraction of HSCs in the context of TGF-I3 activation was tested in a GARP-dependent fashion. Results: Mice lacking GARP in HSCs were protected from developing liver fibrosis. Therapeutically deleting GARP on HSCs alleviated the fibrotic process in established disease. Furthermore, natural killer T cells exacerbated hepatic fibrosis by inducing GARP expression on HSCs through IL-4 production. Mechanistically, GARP facilitated fibrogenesis by activating TGF-I3 and enhancing endothelin-1-mediated HSC contraction. Functional GARP was expressed on human HSCs and significantly upre-gulated in the livers of patients with fibrosis. Lastly, deletion of GARP on HSCs did not augment inflammation or liver damage. Conclusions: GARP expressed on HSCs drives the development of liver fibrosis via cell contraction-mediated activation of latent TGF-I3. Considering that systemic blockade of TGF-I3 has major side effects, we highlight a therapeutic niche provided by GARP and surface-mediated TGF-I3 activation. Thus, our findings suggest an important role of GARP on HSCs as a promising target for the treatment of liver fibrosis.(c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据